Company Description
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom.
The company was incorporated in 2011 and is based in Rolle, Switzerland.
| Country | Switzerland |
| Founded | 2011 |
| IPO Date | Jul 23, 2021 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 415 |
| CEO | Jurgi Camblong |
Contact Details
Address: La PiEce 12 Rolle, 1180 Switzerland | |
| Phone | 41 21 694 10 60 |
| Website | sophiagenetics.com |
Stock Details
| Ticker Symbol | SOPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001840706 |
| CUSIP Number | H82027105 |
| ISIN Number | CH1125843347 |
| SIC Code | 7374 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jurgi Camblong M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Ross Jordan Muken B.Sc. | President |
| George A. Cardoza M.B.A. | Executive Vice President and Chief Financial Officer |
| Abhimanyu Verma | Executive Vice President and Chief Technology Officer |
| Dr. Zhenyu Xu Ph.D. | Executive Vice President and Chief Scientific Officer |
| Kellen Sanger | Head of Strategy and Investor Relations |
| Daan van Well L.L.M., M.B.A. | Executive Vice President and Chief Legal and Compliance Officer |
| Kevin Puylaert | SVice President and Chief Sales Officer |
| Manuela Da Silva Valente B.A. | Executive Vice President and Chief People Officer |
| Dr. Philippe Menu M.B.A., M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 144 | Filing |
| Jun 25, 2026 | 144 | Filing |
| Jun 22, 2026 | 144 | Filing |
| Jun 22, 2026 | 144 | Filing |
| Jun 22, 2026 | 6-K | Report of foreign issuer |
| Jun 22, 2026 | 6-K | Report of foreign issuer |
| Jun 17, 2026 | 424B5 | Filing |
| Jun 16, 2026 | 424B5 | Filing |
| Jun 4, 2026 | 6-K | Report of foreign issuer |
| May 19, 2026 | 144 | Filing |